Delivery of recombinant or therapeutically mutated TGF-β3 at the time of injury has been shown to reduce scar formation in skin (Shah et al., 1995; Waddington et al., 2010), lip (Hosokawa et al., 2003), oral mucosa (OM) (Ohno et al., 2011) and VFM (Ohno et al., 2012) in preclinical models, and recombinant TGF-β3 has demonstrated safety and efficacy in phase I and II human clinical trials (Ferguson et al., 2009; McCollum et al., 2011; So et al., 2011). This evidence concerns the gene TGFB3 and ocular melanoma.